Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Malt
Reexamination Certificate
2006-08-01
2006-08-01
Saunders, David (Department: 1644)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Malt
C424S193100, C530S402000, C530S403000
Reexamination Certificate
active
07083959
ABSTRACT:
The present invention relates to a method of specifically suppressing an undesired immune response in a mammal suffering from such a response. The method comprises:i) preparing a construct comprising at least one discrete antigenically recognizable moiety corresponding to an antigenic determinant of an antigen causing the undesired immune response bound to a pharmacologically acceptable carrierwherein the number of the moieties bound to the carrier and the spacing of the moieties on the carrier are such that the construct does not elicit an immune response to the moieties but does directly compete with the antigen for receptors on an immunocompetent cell that recognizes the determinant, and thereby the construct specifically suppresses the undesired immune response; andii) administering the construct to the mammal in an amount such that suppression of the undesired immune response is effected. The invention further relates to constructs suitable for use in the above method and to methods of making same.
REFERENCES:
patent: 4191668 (1980-03-01), Katz
patent: 4220565 (1980-09-01), Katz
patent: 4222907 (1980-09-01), Katz
patent: 4253995 (1981-03-01), Katz
patent: 4253996 (1981-03-01), Katz
patent: 4276206 (1981-06-01), Katz
patent: 4722899 (1988-02-01), Hamaoka et al.
patent: 5126131 (1992-06-01), Dintzis et al.
patent: 5268454 (1993-12-01), Barstad et al.
patent: 5370871 (1994-12-01), Dintzis et al.
Katz et al (1973) Induction of Immunological Tolerance in Bone Marrow—Derived Lymphoxytes of the IgE Antibody Class PNAS 70(10):2776-2780.
Dintzis et al, Inhibition of Anti-DNP Antibody Formation by High Doses of DNP-Polyacrylamide Molecules; Effects of Hapten Density and Hapten Valence, The Journal of Immunology, vol. 135, No. 1, pp. 423-427, Jul. 1985.
Dintzis et al, Molecular Determinants of Immunogenicity: The Immunon Model of Immune Response, Proc. Natl. Acad. Sci. USA, vol. 73, No. 10, pp. 3671-3675, Oct. 1976.
Vogelstein et al, Specific Cellular Stimulation in the Primary Immune Response: A Quantized Model, Proc. Natl. Acad. Sci. USA, vol. 79, pp. 395-399, Jan. 1982.
Dintzis et al, Specific Cellular Stimulation in the Primary Response: Experimental Test of a Quantized Model, Proc. Natl. Acad. Sci. USA, vol. 79, pp. 884-888, Feb. 1982.
Dintzis et al, Studies on the Immunogenicity and Tolerogenicity of T—Independent Atigens, The Journal of Immunology, vol. 131, No. 5, Nov. 1983, pp. 2196-2203.
Fundneberg, H.H., Basic and Clinical Immunology, published 1980, pp. 44-52.
Dintzis Howard M.
Dintzis Renee Z.
Pillsbury Winthrop Shaw & Pittman LLP
Saunders David
The Johns Hopkins University
LandOfFree
Therapeutic suppression of specific immune responses by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic suppression of specific immune responses by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic suppression of specific immune responses by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3712523